Sjogren’s Syndrome – Landscape & Forecast – Disease Landscape & Forecast

Sjögren’s syndrome (SS) is a progressive autoimmune disease characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands; the disease may occur alone (primary SS) or with a comorbid autoimmune condition (secondary SS). Symptomatic therapies to treat dry eyes, dry mouth, and/or specific extraglandular manifestations are the cornerstone of disease management. Systemic manifestations are most often treated with hydroxychloroquine or, in severe cases, systemic immunomodulators (e.g., azathioprine, methotrexate). Therapies with disease-modifying potential are in development for SS (e.g., Novartis’s iscalimab and ianalumab and Horizon Therapeutic’s dazodalibep), targeting key pathways believed to drive pathological processes in the disease. These putative disease-modifying therapies have the potential to transform the management of SS, although SS is an indication in which such success has historically been a challenge.

Questions answered

• How large is the SS population and how will its size change over time?
• How is SS currently managed? What are the current treatments, and what drives their use?
• Which unfulfilled clinical needs are the most pressing?
• Which pipeline products are the most promising, and what sales might they garner in the SS market? What therapies of note are progressing in earlier phases?
• What clinical roles will Novartis’s iscalimab and ianalumab, and Horizon Therapeutics’ dazodalibep play in the evolving SS treatment landscape?
• What are the drivers of and constraints in the SS market, and how will the market evolve through 2032?

Content highlights

• Geographies: United States and EU5.
• Primary research: Six country-specific interviews with thought-leading SS specialists supported by survey data collected for this study.
• Epidemiology: Diagnosed and drug-treated prevalent cases of SS by country, diagnosed prevalence by subtype.
• Forecast: Drug-level sales and patient share of key SS therapies through 2032.
• Emerging therapies: Phase 3/PR: 1 drug; Phase 2: 7+ drugs; coverage of select early-phase products.

Product description

Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Niche & Rare Disease Landscape & Forecast introduces a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.